Biomarkers in Patients With Suspected HFpEF

RecruitingOBSERVATIONAL
Enrollment

1,028

Participants

Timeline

Start Date

February 2, 2023

Primary Completion Date

September 29, 2025

Study Completion Date

September 29, 2026

Conditions
Heart FailureObesityHeart Failure With Preserved Ejection Fraction
Interventions
DIAGNOSTIC_TEST

Plasma biomarker levels

"This study will investigate the diagnostic utility and performance of:~1. Alternative cut-offs for NT-proBNP to identify HF(pEF) in people with suspected HF and obesity, in whom~2. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and obesity.~3. Novel candidate biomarkers to identify HF(pEF) in people with suspected HF and NT-proBNP \<125 ng/L~4. The prevalence of HF in people with suspected HF and low NT-proBNP \<125 ng/L).~The diagnosis of heart failure will be determined according to international guidelines, when there are symptoms and/or signs of HF in association with objective evidence of cardiac structural and/or functional abnormalities consistent with the presence of LV diastolic dysfunction/raised LV filling pressures. Non-invasive testing with rest and diastolic stress echocardiography will be used to evaluate for evidence of raised filling pressures, in order to make the study procedures applicable to usual clinical practice."

Trial Locations (3)

G128TA

RECRUITING

Glasgow Royal Infirmary, Glasgow

G51 4TF

RECRUITING

New Victoria Hospital, Glasgow

RECRUITING

Queen Elizabeth University Hospital, Glasgow

All Listed Sponsors
collaborator

University of Glasgow

OTHER

collaborator

Roche Diagnostics GmbH

INDUSTRY

lead

NHS Greater Glasgow and Clyde

OTHER